Skip to main content

Table 4 Summary of studies of gemcitabine-docetaxel therapy in osteosarcoma

From: Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?

Author Journal Center Year No. ORR DCR
Fariba Navid [11] Cancer St. Jude Children’s Research Hospital 2008 10 3 (30%) 4 (40%)
Yasmin Gosiengfiao [23] J Pediatr Hematol Oncol Children’s Memorial Hospital 2012 4 1 (25%) 3 (75%)
Louis Rapkin [14] Pediatr Blood Cancer Emory University 2012 5 0 3 (60%)
Elizabeth Fox [18] The Oncologist MD Anderson Cancer Center 2012 14 1 (7%) NAa
Weixiang Qi [17] Jpn J Clin Oncol Shanghai Jiaotong University 2012 18 1 (5.6%) 4 (22.3%)
Aina He [13] Int J Clin Oncol Shanghai Jiaotong University 2013 23 3 (13%) 10 (47.8%)
Wen Xi Yu [12] Oncology Letters Shanghai Jiaotong University 2014 21 2 (9.5%) 6 (28.5%)
Bong Sup Song [15] Pediatr Blood Cancer Korea Cancer Center Hospital 2014 17 2 (11.8%) 7 (41.2%)
E. Palmerini [16] BMC Cancer Instituto Ortopedico Rizzoli 2016 35 6 (17.1%) 20 (57.1%)
Lee JA [24] Pediatr Blood Cancer Korea Cancer Center Hospital 2016 53b 5 (14.3%) 10 (28.6%)
Tanaka [27] World J Surg Oncol Japan Clinical Oncology Group 2016 17 (134)c 0 7 (41.2%)
Takahashi [28] Plos One Tohoku University Hospital 2017 5 (42)d 0 4 (80%)
  1. aNA not available
  2. bResponse datas were available in 35 patients
  3. cThis study included 134 patients with bone and soft tissue sarcoma, during which 17 (12.7%) patients were diagnosed with osteosarcoma
  4. dThis study included 42 patients with bone and soft tissue sarcoma, during which 5 (11.9%) patients were diagnosed with osteosarcoma